Effects of nicorandil on myocardial infarct size in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: study design and protocol for the randomized controlled trial

Previous studies have shown that nicorandil has a protective effect on cardiomyocytes. However, there is no study to investigate whether perioperative intravenous nicorandil can further reduce the myocardial infarct size in patients with ST-segment elevation myocardial infarction (STEMI) compared to...

Descripción completa

Detalles Bibliográficos
Autores principales: JIANG, Xiao-Si, TIAN, Li-Chao, JIANG, Zi-Chao, ZOU, Yu-Ting, LI, Ping, YANG, Xin-Chun, SU, Xi, TIAN, Jin-Wen, SHI, Bei, LI, Zong-Zhuang, LI, Yong-Jun, YANG, Ren-Qiang, QIAN, Geng, CHEN, Yun-Dai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Science Press 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7475214/
https://www.ncbi.nlm.nih.gov/pubmed/32952527
http://dx.doi.org/10.11909/j.issn.1671-5411.2020.08.002
Descripción
Sumario:Previous studies have shown that nicorandil has a protective effect on cardiomyocytes. However, there is no study to investigate whether perioperative intravenous nicorandil can further reduce the myocardial infarct size in patients with ST-segment elevation myocardial infarction (STEMI) compared to the current standard of percutaneous coronary intervention (PCI) regimen. The CHANGE (China-Admini stration of Nicorandil Group) study is a multicenter, prospective, randomized, double-blind and parallel-controlled clinical study of STEMI patients undergoing primary PCI in China, aiming to evaluate the efficacy and safety of intravenous nicorandil in ameliorating the myocar dial infarct size in STEMI patients undergoing primary PCI and provide evidence-based support for myocardial protection strategies of STEMI patients.

Ejemplares similares